Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation-Reference-Cited by-同舟云学术

Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation

Published:2020-08-28 Issue:35 Volume:99 Page:e22064
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Sumiyoshi Ritsu,Tashiro Haruko,Saito Sumiko,Matsuo Takuji,Yamamoto Tadashi,Matsumoto Kensuke,Ooi Jun,Shirafuji Naoki

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference17 articles.

1. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change;Christopeit;J Clin Oncol,2013

2. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment;Rautenberg;Int J Mol Sci,2019

3. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation;Wadleigh;Blood,2003

4. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial;Lambert;Haematologica,2019

5. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial;Amadori;J Clin Oncol,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin;Cancers;2021-09-11

2. Gemtuzumab-ozogamicin;Reactions Weekly;2020-11